Journal Of The American Medical Association Publishes Phase 3 LAPLACE-2 Study Showing Evolocumab Significantly Reduced LDL Cholesterol In Patients On Statins Regardless Of Statin Dose
PR Newswire - 55 mins ago
Amgen (NASDAQ:AMGN) today announced the publication of data from the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) study in the Journal of the American Medical Association (JAMA). Results from the 12-week study, which evaluated 1,896 patients with high cholesterol, showed treatment with subcutaneous evolocumab (140 mg every two weeks or 420 mg monthly) in combination with different daily doses of statin therapy significantly reduced mean low-density lipoprotein cholesterol (LDL-C) regardless of statin dose. These findings were initially presented at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) in March 2014.
Midday Glance: Biotechnology companies
AP - Tue May 13, 12:43PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
What Biotech Investors Need to Know About Phase 2 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - Tue May 13, 10:38AM CDT
Phase 2 trials occupy an interesting place in a clinical development plan. Theoretically, phase 2 is just the next step after phase 1, advancing a drug to tests of efficacy after safety and tolerability are established. Phase 2 is generally when a...
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
M2 - Tue May 13, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs46lc/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. The pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. The two drug makers will combine and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline. Revenues of major pharma companies are broke out by these therapeutic areas in the report, Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023. Novartis has about 1/3 of its pharmaceutical revenues coming from oncology products. Thus it certainly makes sense to build that area, according to Kalorama's report. Novartis is currently number 2 in the world for cancer therapies behind Roche. The firm does not think that Novartis rises in market share from the deal, but it does believe it will certainly strengthen its position and maintain its wide distance from the 3rd competitor in the market. Although Kalorama also thinks the move benefits Glaxo Smith Kline, there could be less advantages for the company in the deal than for Novartis. Novartis will keep influenza vaccines, as part of the deal. This could work out to be highly beneficial, vaccines is a competitive area. The positions of companies do shift somewhat from year to year with vacillations in flu vaccines and other specific products, although for the past few years, Glaxo has led the market and Novartis has trailed at a distance. Furthermore, in pediatric vaccines GSK is also a major contributor and leader and solidifying this position is good but is not really helpful in the overall picture. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 estimates current sales for major pharmaceutical companies, breaks out revenue by therapeutic area and discusses general trends in the industry. Market watchers can use the report to understand developments in greater context than news media can provide. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 Top 25 Companies Mentioned - Abbvie, inc. - Actavis - Amgen, inc. - Astellas - Astra Zeneca plc - Baxter international - Bayer AG - Boehringer Ingelheim gmbh - Bristol-myers Squibb Company - Daiichi Sankyo - Eli Lilly and Company - Gilead Sciences - Glaxosmithkline PLC - Johnson & johnson - Merck & Co., inc. - Merck KGAA - Mylan - Novartis AG - Novo nordisk - Otsuka Pharmaceutical - Pfizer, inc. - Roche ltd. - Sanofi - Takeda Pharmaceutical co., LTD - Teva Pharmaceutical Industries, Ltd. For more information visit http://www.researchandmarkets.com/research/fs46lc/top_25
Early Glance: Biotechnology companies
AP - Tue May 13, 9:41AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Insider Trading Alert - AMGN, ACM And CWEI Traded By Insiders
at The Street - Tue May 13, 9:15AM CDT
Stocks with insider trader activity include AMGN, ACM and CWEI
Final Glance: Biotechnology companies
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Amgen's Breakaway from Cancer® Honors Four California Cancer Survivors During The Ninth Annual Amgen Tour of California
PR Newswire - Mon May 12, 3:38PM CDT
Amgen today announced that four individuals who are an inspiration for others affected by cancer have been selected as Breakaway from Cancer® Champions. They will be honored as part of Amgen's Breakaway from Cancer national initiative, designed to raise awareness of the important resources available to those impacted by cancer - from prevention to survivorship - during the ninth annual Amgen Tour of California, the nation's largest and most prestigious professional cycling race, which takes place May 11-18, 2014.
Amgen Names Steven K. Galson, Senior Vice President, Global Regulatory Affairs And Safety
PR Newswire - Mon May 12, 3:03PM CDT
Amgen (NASDAQ: AMGN) today announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. Galson will report to Sean E. Harper, M.D., executive vice president, Research and Development, and will be responsible for all regulatory and patient safety functions across Amgen.
Amgen-AstraZeneca Psoriasis Drug Scores - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:50PM CDT
Amgen (AMGN) and AstraZeneca's (AZN) brodalumab achieved the primary and secondary endpoints in a late-stage study.
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Amgen Is Down 6.6% (AMGN)
Comtex SmarTrend(R) - Mon May 12, 11:31AM CDT
When Amgen (NASDAQ:AMGN) reported earnings 20 days ago on April 22nd, 2014, analysts, on average, expected the company to report earnings of $1.94 on sales of $4.8 billion. Amgen actually reported earnings of $1.87 per share on sales of $4.5 billion, missing EPS estimates by $0.07 and missing revenue estimates by $231.1 million. Since the company's report, shares of Amgen have fallen from $119.30 to $111.48, representing a loss of 6.6% in the past 20 days.
Genelux Corporation Announces Former Amgen and Abbott Executives to Succeed Founder Aladar A. Szalay, Ph.D., as CEO, Chairman of the Board
Marketwire - Mon May 12, 9:59AM CDT
Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced that Aladar Szalay, PhD has chosen to retire from the positions of Chairman, President and CEO of Genelux for personal reasons. Dr. Szalay will continue to serve as chief scientific advisor to the CEO and remain on the company's board of directors as chairman emeritus. Effective May 2, 2014, pharmaceutical industry veteran and long-time Amgen executive, Mr. Thomas Zindrick will serve as president and CEO. Mr. James L. Tyree, formerly of Abbott will serve as chairman of the board.
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
Critical Alerts For Amgen, UnitedHealth Group, Yahoo, Anheuser-Busch InBev, and Illumina Released By InvestorsObserver
PR Newswire - Mon May 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, UNH, YHOO, BUD, and ILMN.
Kevin Egan Joins Sernova as Chair Business Advisory Board
Marketwire - Mon May 12, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) is pleased to announce that Mr. Kevin M. Egan, President, Borealis Biotechnology LLC, an international biotechnology consulting company, has joined Sernova as Chair of the Business Advisory Board. A Washington-based entrepreneur and investor, Mr. Egan is one of North America's most prolific, biotech entrepreneurs, bringing over 25 years of success-driven experience in biopharma, and commercialization & partnering expertise to Sernova. He has been directly involved in helping to develop blockbuster drugs from two, bell-weather US biotech giants: Amgen and Icos.
This Week in Biotech: Chelsea Therapeutics Finds a Buyer While Corcept Implodes
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 11:15AM CDT
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Amgen
at Investor's Business Daily - Fri May 09, 6:25PM CDT
Amgen (AMGN) and AstraZeneca (AZN) released positive results from a late-stage study of psoriasis drug Brodalumab. Shares of both drugmakers were little changed late.
BayBio Names Henry M. Gunn High School Senior Amgen Bay Area BioGENEius Finalist
Business Wire - Fri May 09, 5:00PM CDT
BayBio today named Henry M. Gunn High School senior Emily Wang of Palo Alto as the winner of the 2014 Amgen Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. As the Amgen Bay Area BioGENEius finalist, Wang will gain insider access to the biotechnology industry by attending the 2014 BIO International Convention in San Diego, the industry's trade conference, where leading companies, scientists and innovators will offer her invaluable advice and first-hand experience on the limitless possibilities within one of the world's most innovative industries.